<DOC>
	<DOC>NCT00387088</DOC>
	<brief_summary>The objective of the study is to evaluate the long-term (one year) efficacy and safety of tiotropium delivered by the Respimat inhaler in patients with COPD. Specifically, the study will examine the effect of treatment on COPD exacerbations.</brief_summary>
	<brief_title>Tiotropium / Respimat One Year Study in COPD.</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>1. Male or female 2. At least 40 years old 3. Smoker or exsmoker 4. Smoking history &gt; 10 packyears 5. Forced Expiratory Volume in 1 Second (FEV1) &lt; 60% predicted 1. Recent history of myocardial infarction, lifethreatening cardiac arrhythmia or hospitalisation for cardiac failure 2. History of asthma or allergic conditions. 3. Malignancy requiring treatment within past 5 years 4. Lifethreatening pulmonary obstruction, cystic fibrosis or clinically evident bronchiectasis 5. Known active tuberculosis 6. Known hypersensitivity to anticholinergic drugs.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>